enfilcon A
DeviceOther names: Avaira® Toric
NCT Number: NCT01706770
The primary objective of thes study is to confirm that the ocular response to the Test lenses are similar to those of the Control lenses when used in a 1 week planned replacement, daily wear modality over a 1-month period.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Advanced Eyecare, Pismo Beach, California, United States
The test lens and control lens were randomized in a 2:1 ratio to evaluate the test lens and control contact lens.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Prior to being considered eligible to participate in this study, each subject MUST:
Exclusion criteria
Subjects may not be enrolled in this study if any of the following apply: The subject is/has:
To be eligible to be randomized for study product a subject must have ALL of the Inclusion Criteria and have NONE of the exclusion criteria present.
To be eligible for lens dispensing (either Test or Control), the subject's study lens contact lens visual acuity must be equal to or better than 20/30 in each eye.
Other names: Avaira® Toric
Other names: Acvuve® Advance®
Time frame: Change from baseline/dispensing visits, post-dispensing visit and all follow-ups visits
The primary safety endpoint are the objective slit lamp findings associated with the enfilcon A contact lenses compared with those same findings reported as associated with the galyfilcon A contact lenses.
The incidence of biomicroscopy findings (0=not present, 4=severe) over the duration of the study with the highest reported grade was chosen for each unique eye. Biomicroscopy measurements were obtained at Baseline/Dispensing (baseline and dispensing visit combined), Post-Dispensing (after lenses were dispensed and allowed to settle) and All Follow-Ups (week 1 visit, week 2 visit, month 1 visit combined). The average grade for unique eyes with findings greater than 0 (none) is compared.
Time frame: Any occurrence from baseline to 1 month visit
The primary safety endpoint are the objective findings of the number of adverse events in unique eyes associated with the enfilcon A contact lenses compared with those same findings as associated with the galyfilcon A contact lenses.
The number of adverse events over the duration of the study was reported for each unique eye (bilateral or unilateral). Observations for adverse events were reported for any occurrence from Baseline through end of month 1 visit.
CooperVision, Inc.
Industry
Evaluation of Enfilcon A Soft Contact Lens Compared to Galyfilcon A Soft Contact Lens
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07168564
Ametropia, Eye Diseases
Bloomington, Indiana, United States
View Trial DetailsNCT06668246
Ametropia, Eye Diseases
Brest, France
View Trial DetailsNCT07104773
Ametropia, Eye Diseases
Waterloo, Ontario, Canada
View Trial DetailsNCT07375589
Ametropia, Eye Diseases
Shanghai, Shanghai Municipality, China
View Trial Details